

IMPACT FACTOR 3.4

Indexed in: PubMed



an Open Access Journal by MDPI

Personalized Medicine and Management of COVID-19

Guest Editors:

Prof. Dr. Weikuan Gu

Department of Orthopedic Surgery and BME-Campbell Clinic, University of Tennessee Health Science Center, Memphis, TN 38163, USA

Prof. Dr. Lotfi Aleya

National Centre for Scientific Research (CNRS 6249), Université de Franche-Comté, F-25030 Besançon, France

Deadline for manuscript submissions:

closed (25 April 2023)

Message from the Guest Editors

COVID-19 poses a major global threat to humankind, inflicting devastating consequences as to public health. Understanding its pathological and epidemiological variation along with providing a personalized treatment will greatly reduce its damage and enhance the preparedness for a future pandemic caused by either COVID-19 or other infectious diseases.

As the pandemic has so far lasted a year and half, studies with solid experimental and a considerable amount of data, particularly on molecular mechanisms and overall genetics, will provide valuable information for both the general public and the scientific community.

We are looking for papers that provide a novel contribution to optimize the personalization of medicine covering all aspects of COVID-19. For example, we welcome papers related to personalized and sex difference in pathological classification, diagnosis, treatment, recovering process, and COVID-19-related sequelae along with the variations in disease epidemiological patterns, transmission and management according to countries, regions, sex and races







IMPACT FACTOR 3.4





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

 Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
Division of Hematologic Malignancies and Cellular Therapy, Duke University,

Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous*))

Contact Us